Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: A large multicenter AGEO study

Journal of Hepatology

Volumn 58, Issue 1, 2013, Pages 81-88

  Zaanan, Aziz ^a,b   Williet, Nicolas ^a   Hebbar, Mohamed ^c   Dabakuyo, Tienhan Sandrine ^d   Fartoux, Laetitia ^e   Mansourbakht, Touraj ^f   Dubreuil, Olivier ^a,b   Rosmorduc, Olivier ^e   Cattan, Stéphane ^c   Bonnetain, Franck ^d   Boige, Valérie ^g   Taïeb, Julien ^a,b  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d CENTRE GEORGES FRANÇOIS LECLERC   (France)

^e HÔPITAL SAINT ANTOINE   (France)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^g INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Chemotherapy; Gemcitabine; Hepatocellular carcinoma; Oxaliplatin; Prognostic factors; Survival

Indexed keywords

GEMCITABINE; OXALIPLATIN;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; DIARRHEA; DISEASE CONTROL; FEMALE; HUMAN; KAPLAN MEIER METHOD; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNIVARIATE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEASIBILITY STUDIES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84871186416     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2012.09.006     Document Type: Article

References (33)

1. D.M. Parkin, F. Bray, J. Ferlay, and P. Pisani Global cancer statistics, 2002 CA Cancer J Clin 55 2005 74 108
2. H.B. El-Serag, and K.L. Rudolph Hepatocellular carcinoma: epidemiology and molecular carcinogenesis Gastroenterology 132 2007 2557 2576
3. A. Smedile, and E. Bugianesi Steatosis and hepatocellular carcinoma risk Eur Rev Med Pharmacol Sci 9 2005 291 293
4. J. Taieb, J.C. Barbare, and P. Rougier Medical treatments for hepatocellular carcinoma (HCC): what's next? Ann Oncol 17 2006 x308 x314
5. P. Rougier, E. Mitry, J.C. Barbare, and J. Taieb Hepatocellular carcinoma (HCC): an update Semin Oncol 34 2007 S12 S20
6. C. Hsu, Y.C. Shen, C.C. Cheng, F.C. Hu, and A.L. Cheng Geographic difference in survival outcome for advanced hepatocellular carcinoma: implications on future clinical trial design Contemp Clin Trials 31 2010 55 61
7. J.M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane, and J.F. Blanc Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
8. A.L. Cheng, Y.K. Kang, Z. Chen, C.J. Tsao, S. Qin, and J.S. Kim Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial Lancet Oncol 10 2009 25 34
9. A. Burroughs, D. Hochhauser, and T. Meyer Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum Lancet Oncol 5 2004 409 418
10. J. Taieb, L. Bonyhay, L. Golli, M. Ducreux, E. Boleslawski, and J.M. Tigaud Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules Cancer 98 2003 2664 2670
11. A. Asnacios, L. Fartoux, O. Romano, C. Tesmoingt, S.S. Louafi, and T. Mansoubakht Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study Cancer 112 2008 2733 2739
12. S. Louafi, V. Boige, M. Ducreux, L. Bonyhay, T. Mansourbakht, and T. de Baere Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study Cancer 109 2007 1384 1390
13. V. Boige, J. Taieb, M. Hebbar, D. Malka, T. Debaere, and L. Hannoun Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma: a multicenter phase II study with dose adjustment according to baseline serum bilirubin level Eur J Cancer 42 2006 456 459
14. A.X. Zhu, L.S. Blaszkowsky, D.P. Ryan, J.W. Clark, A. Muzikansky, and K. Horgan Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma J Clin Oncol 24 2006 1898 1903
15. J. Bruix, M. Sherman, J.M. Llovet, M. Beaugrand, R. Lencioni, and A.K. Burroughs Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver J Hepatol 35 2001 421 430
16. J.P. Caussanel, F. Levi, S. Brienza, J.L. Misset, M. Itzhaki, and R. Adam Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate J Natl Cancer Inst 82 1990 1046 1050
17. A.K. Nowak, P.K. Chow, and M. Findlay Systemic therapy for advanced hepatocellular carcinoma: a review Eur J Cancer 40 2004 1474 1484
18. R.G. Gish, C. Porta, L. Lazar, P. Ruff, R. Feld, and A. Croitoru Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin J Clin Oncol 25 2007 3069 3075
19. C.L. Lai, P.C. Wu, G.C. Chan, A.S. Lok, and H.J. Lin Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial Cancer 62 1988 479 483
20. G. Lombardi, F. Zustovich, F. Farinati, U. Cillo, A. Vitale, and G. Zanus Pegylated liposomal doxorubicin and gemcitabine in patients with advanced hepatocellular carcinoma: results of a phase 2 study Cancer 117 2011 125 133
21. S. Qin, Y. Bai, S. Ye, J. Fan, H. Lim, and J.Y. Cho Phase III study of oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX4) versus doxorubicin as palliative systemic chemotherapy in advanced HCC in Asian patients J Clin Oncol 28 2010 15s [suppl.; abstr 4008]
22. T.W. Leung, Y.Z. Patt, W.Y. Lau, S.K. Ho, S.C. Yu, and A.T. Chan Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma Clin Cancer Res 5 1999 1676 1681
23. W. Yeo, T.S. Mok, B. Zee, T.W. Leung, P.B. Lai, and W.Y. Lau A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/ doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma J Natl Cancer Inst 97 2005 1532 1538
24. M. Hebbar, O. Ernst, S. Cattan, S. Dominguez, C. Oprea, and P. Mathurin Phase II trial of docetaxel therapy in patients with advanced hepatocellular carcinoma Oncology 70 2006 154 158
25. Z. Guan, Y. Wang, S. Maoleekoonpairoj, Z. Chen, W.S. Kim, and V. Ratanatharathorn Prospective randomised phase II study of gemcitabine at standard or fixed dose rate schedule in unresectable hepatocellular carcinoma Br J Cancer 89 2003 1865 1869
26. J. Alexandre, J.M. Tigaud, M. Gross-Goupil, J.M. Gornet, D. Romain, and D. Azoulay Combination of topotecan and oxaliplatin in inoperable hepatocellular cancer patients Am J Clin Oncol 25 2002 198 203
27. K. Stuart, J. Tessitore, J. Rudy, N. Clendennin, and A. Johnston A Phase II trial of nolatrexed dihydrochloride in patients with advanced hepatocellular carcinoma Cancer 86 1999 410 414
28. S. Collette, F. Bonnetain, X. Paoletti, M. Doffoel, O. Bouche, and J.L. Raoul Prognosis of advanced hepatocellular carcinoma: comparison of three staging systems in two French clinical trials Ann Oncol 19 2008 1117 1126
29. C. Tournoux-Facon, X. Paoletti, J.C. Barbare, O. Bouche, P. Rougier, and L. Dahan Development and validation of a new prognostic score of death for patients with hepatocellular carcinoma in palliative setting J Hepatol 54 2011 108 114
30. L.X. Qin, and Z.Y. Tang The prognostic significance of clinical and pathological features in hepatocellular carcinoma World J Gastroenterol 8 2002 193 199
31. S.R. Vora, H. Zheng, Z.K. Stadler, C.S. Fuchs, and A.X. Zhu Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma Oncologist 14 2009 717 725
32. S.L. Chan, F.K. Mo, P.J. Johnson, E.P. Hui, B.B. Ma, and W.M. Ho New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy J Clin Oncol 27 2009 446 452
33. M. Kudo, H. Chung, S. Haji, Y. Osaki, H. Oka, and T. Seki Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score Hepatology 40 2004 1396 1405